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Medline and the National Health Service Economic Evaluation Database (NHSEED) 
were searched from their inception up to October 2009. Included studies were those 
full economic evaluations describing both costs and consequences of a) CT angiogra-
phy; b) MRI; c) SPECT; and d) stress ECHO in the diagnosis of CAD. Article selection 
was performed by independent pairs of researchers. Target data for extraction 
included: study ﬁrst author and year of publication, imaging tests compared, type of 
economic analysis, reported costs and outcomes, incremental cost-effectiveness ratio 
(ICER), currency, and patient characteristics (i.e., known or suspected CAD and risk 
of CAD). The primary outcome of interest for the present systematic review was the 
ICER of each imaging test in relation to another test of interest being compared. 
RESULTS: A total of 12 studies were identiﬁed. Overall, of the selected strategies, 
stress ECHO was the most compared, followed by SPECT, and CT angiography and 
MRI. Results showed that (despite fewer studies) CT angiography was considered 
cost-effective in all comparisons, however in speciﬁc situations such as in the presence 
of high likelihood or prevalence of CAD or versus stress ECHO and MRI (no com-
parison was found against SPECT). Under base-case (average) situations, stress ECHO 
was reported to be relatively cost-effective, especially in contrast with SPECT and 
MRI, but not CT angiography. SPECT follows with few positive cost-effectiveness 
results, and MRI did not achieve any cost-effectiveness over the other remaining 
strategies. CONCLUSIONS: Therefore, according to the published economic data 
from the literature, a cost-effectiveness ranking is proposed for the four analyzed 
cardiac imaging strategies as follows: CT angiography (in the presence of high likeli-
hood or prevalence of CAD) > stress ECHO > SPECT > MRI.
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OBJECTIVES: Use of venous thromboembolism (VTE) prophylaxis among hospital-
ized patients is very low at approximately 42% (Goldhaber 2004). This analysis 
quantiﬁes whether thromboprophylactic treatment with dalteparin in acutely ill 
patients is cost saving due to avoided VTE. METHODS: Randomized clinical trial 
VTE data from the Prevention of Venous Thromboembolism in Immobilized Patients 
(PREVENT) trial were used to determine dalteparin and placebo VTE event rates. 
Costs were obtained from two published sources Oster et al. (2004) and MacDougall 
et al. (2006). Oster et al. reports on short term charged costs (90 days) while Mac-
Dougall et al. on long term (one year) paid costs. Costs were converted to 2008 US 
dollars using the CPI. Cost for dalteparin was calculated as $29.34 (2009 WAC 
pricing) for 5000 IU once daily for 14 days, while the cost of placebo is zero. 
RESULTS: In PREVENT, 2991 patients were randomized (1518 to dalteparin, 1473 
to placebo). Dalteparin patients experienced 32 VTE events while placebo had 64. 
The short term cost of in-hospital VTE was $17,552 higher than matched controls (P 
< 0.01) and short term post-discharge VTE cost was $5765 higher than matched 
controls (P = 0.01) (Oster et al.), while the long term annual adjusted mean total 
claims cost was $30,400 (MacDougall et al.). In aggregate, VTE events cost $1,393,914 
for dalteparin patients versus $1,550,112 for placebo in the short term with a cost 
savings of $156,197 for patients utilizing dalteparin. The total annual costs for treat-
ing 32 VTE patients plus cost of dalteparin was $1,783,425 as compared to $2,329,132 
for treating 64 VTE patients on placebo, giving an annual cost savings of $545,708 
for utilizing dalteparin. CONCLUSIONS: Thromboprophylactic treatment with dalte-
parin reduces short term costs by $156,197 ($102.89 per person) and long term annual 
costs by $545,708 ($359.49 per person) in acutely ill patients at risk for VTE.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic disabling condition 
that affects both adults and children. The aim of this study was to evaluate the cost-
effectiveness of sildenaﬁl to manage PAH in pediatric (<18 years), functional class III, 
patients, who have failed previously to calcioantagonists, from the Mexican institu-
tional perspective. METHODS: A ﬁve-state Markov model was performed to estimate 
one year costs and health consequences (one-month cycle). Effectiveness measures 
were: increase in cardiac index (%) and exercise tolerance (%), as well as reduction 
in pulmonary vascular resistance (%), hospital length of stay (LOS, days) and discon-
tinuation rate due to adverse events. Transition probabilities were obtained from a 
meta-analysis involving national and international published literature. Doses of com-
parators used in the assessment were sildenaﬁl (60 mg/day) and bosentan (125 mg/
day, reference alternative). Resource use and costs were obtained from hospital records 
(n = 120) from the Instituto Mexicano del Seguro Social. Costs include hospital stay, 
laboratory and respiratory function tests, imagenology, drugs and adverse events 
management. The model was validated according to international guidelines. Sensitiv-
ity analyses were performed employing bootstrapping techniques. RESULTS: Per 
patient associated costs for sildenaﬁl, and bosentan were [CI 95%]: US$13,373 
[US$11,965–US$15,495] and US$20,110 [US$19,589–US$20,631], respectively. 
Sildenaﬁl is associated to an increase of 8.05% [7.87%–8.24%] in cardiac index and 
of 10.14% [9.96%–10.33%] in exercise tolerance, as well as to a reduction of 1.5% 
[1.32%–1.68%] in pulmonary vascular resistance, 11.54 [11.36–11.72] in discontinu-
ation rate (per 1000) and 8.90 days [8.72 days–9.09 days] in LOS, respectively. In 
consequence, sildenaﬁl represents the most attractive therapy to manage PHA in terms 
of cost-effectiveness. CONCLUSIONS: In the Mexican institutional setting, sildenaﬁl 
demonstrated to be a cost-saving therapy to manage PHA in pediatric, functional class 
III, patients,wich should be considered in order to allocate institutional resources 
efﬁciently.
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OBJECTIVES: Updated clinical practice guidelines recommend antithrombotic agents 
to minimize complications and deaths following UA/NSTEMI events. The purpose of 
this study was to estimate the cost-effectiveness of different antithrombotic agents in 
the management of UA/NSTEMI, from the institutional perspective. METHODS: A 
seven-state Markov model was performed to estimate health and economic conse-
quences during a time horizon of ﬁve weeks (one–week cycles). Effectiveness measures 
were reduction in incidence of acute myocardial infarct (AMI) and recurrence of 
angina, as well as avoided events of myocardial revascularization and deaths associ-
ated to acute coronary syndrome. Transition probabilities were obtained from a 
meta-analysis employing international published literature. Doses of comparators 
were: dalteparin (240 UI/kg/day); enoxaparin (2 mg/kg/day); fondaparinux(5 mg/
day); nadroparin(172 IU/kg/day) and unfractionated heparin(UFH 15,000 IU/day). 
Resource use was obtained from the Social Security Mexican Institute hospital records 
(n = 5000). Costs were extracted from government and institutional sources and 
include hospitalization, drugs, medical procedures, imagenology, laboratory tests and 
adverse events management. Probabilistic sensitivity analyses were performed employ-
ing bootstrapping techniques. Acceptability curves were constructed. RESULTS: 
Dalteparin, enoxaparin, fondaparinux, nadroparin and UHF (reference alternative) 
associated costs per patient were: US$2501 (+19%), US$2531 (+20%), US$2226 
(+6%), US$2556 (+21%) and US$2179, respectively. Dalteparin is the only alternative 
that exhibits better health outcomes than reference in all considered effectiveness 
measures (p < 0.05 in AMI and myocardial revascularization). Incremental cost-
effectiveness ratios (ICER [CI95%]) for dalteparin compared to UHF were US$10,916 
[US$10,703-US$11,128] and US$3,509 [US$3,440-US$3,577], per additional AMI 
reduced and additional myocardial revascularization avoided, respectively. At a will-
ingness to pay of US$15,800 per additional AMI avoided, acceptability curves showed 
that the probability that dalteparin be cost-effective is close to one, while for enoxa-
parin is negligible. CONCLUSIONS: Regarding AMI reduction and avoided myocar-
dial revascularization, dalteparin represents a cost-effective antithrombotic therapy in 
Mexican patients who suffered UA/NSTEMI due its higher efﬁcacy and reasonable 
incremental costs.
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OBJECTIVES: The purpose was to conduct a cost-effectiveness analysis (CEA) of 
enoxaparin versus fondaparinux in the treatment of deep-vein thrombosis (DVT) in 
Poland. METHODS: Data concerning efﬁcacy and safety of compared therapies were 
taken from the clinical-effectiveness analysis which was based on the systematic litera-
ture review. Due to lack of statistically signiﬁcant differences in comparison of enoxa-
parin versus fondaparinux, economic proﬁtability estimation was performed as a 
cost-minimisation analysis. Decision model was created by using MS Excel. Total costs 
of analysed therapies were estimated from the perspective of both payers in Poland 
(National Health Fund and patient). The minimisation analysis involved comparison 
of treatment with enoxaparin (1 mg/kg body mass, twice daily) versus fondaparinux 
(5; 7,5 or 10 mg—depending on the patient’s body mass, once daily). The time horizon 
of the analysis was 3 months (consistent with clinical trials). It was assumed that 
efﬁciency of interventions in that period of observation was constant. The costs were 
not discounted. The stability of obtained results was checked in one-way and two-way 
sensitivity analysis through change of key parameters and assumptions of the model. 
RESULTS: The results of the cost-minimisation analysis are as following: treatment 
of one patient using enoxaparin in the 3 month time horizon is 312.50 PLN cheaper 
than fondaparinux therapy. Clinical effects of assessed treatment strategies are com-
parable, based on the data from randomised clinical trials. One-way and two-way 
sensitivity analysis proved that therapy with enoxaparin is a less costly than with 
fondaparinux in the treatment of deep-vein thrombosis for most parameters taken into 
account in the sensitivity analysis. CONCLUSIONS: Treatment of deep-vein throm-
bosis using enoxaparin is a less expensive option in comparison with fondaparinux 
from both payers’ perspective (National Health Fund and patient) in Poland.
